These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32003991)

  • 1. Biomimetic Macrocyclic Inhibitors of Human Cathepsin D: Structure-Activity Relationship and Binding Mode Analysis.
    Houštecká R; Hadzima M; Fanfrlík J; Brynda J; Pallová L; Hánová I; Mertlíková-Kaiserová H; Lepšík M; Horn M; Smrčina M; Majer P; Mareš M
    J Med Chem; 2020 Feb; 63(4):1576-1596. PubMed ID: 32003991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based optimization of non-peptidic Cathepsin D inhibitors.
    Grädler U; Czodrowski P; Tsaklakidis C; Klein M; Werkmann D; Lindemann S; Maskos K; Leuthner B
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4141-50. PubMed ID: 25086681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers.
    Anantaraju HS; Battu MB; Viswanadha S; Sriram D; Yogeeswari P
    Mol Divers; 2016 May; 20(2):521-35. PubMed ID: 26563150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases.
    Binkert C; Frigerio M; Jones A; Meyer S; Pesenti C; Prade L; Viani F; Zanda M
    Chembiochem; 2006 Jan; 7(1):181-6. PubMed ID: 16307463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors.
    Majer P; Collins JR; Gulnik SV; Erickson JW
    Protein Sci; 1997 Jul; 6(7):1458-66. PubMed ID: 9232647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrid 2D/3D-quantitative structure-activity relationship and modeling studies perspectives of pepstatin A analogs as cathepsin D inhibitors.
    Arodola OA; Soliman ME
    Future Med Chem; 2018 Jan; 10(1):5-26. PubMed ID: 29235371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design.
    Baldwin ET; Bhat TN; Gulnik S; Hosur MV; Sowder RC; Cachau RE; Collins J; Silva AM; Erickson JW
    Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6796-800. PubMed ID: 8393577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
    Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
    Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of a low molecular weight inhibitor from Streptomyces sp. MBR04 with human cathepsin D: implications in mechanism of inactivation.
    Menon V; Rao M
    Appl Biochem Biotechnol; 2014 Nov; 174(5):1705-23. PubMed ID: 25141983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D.
    Kick EK; Roe DC; Skillman AG; Liu G; Ewing TJ; Sun Y; Kuntz ID; Ellman JA
    Chem Biol; 1997 Apr; 4(4):297-307. PubMed ID: 9195867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
    Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
    Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of potent macrocyclic renin inhibitors.
    Sund C; Belda O; Wiktelius D; Sahlberg C; Vrang L; Sedig S; Hamelink E; Henderson I; Agback T; Jansson K; Borkakoti N; Derbyshire D; Eneroth A; Samuelsson B
    Bioorg Med Chem Lett; 2011 Jan; 21(1):358-62. PubMed ID: 21112780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and bioactivities of tasiamide B derivatives as cathepsin D inhibitors.
    Li Z; Bao K; Xu H; Wu P; Li W; Liu J; Zhang W
    J Pept Sci; 2019 Apr; 25(4):e3154. PubMed ID: 30734395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Aminoquinazolin-4(3H)-one based plasmepsin inhibitors with improved hydrophilicity and selectivity.
    Rasina D; Stakanovs G; Borysov OV; Pantelejevs T; Bobrovs R; Kanepe-Lapsa I; Tars K; Jaudzems K; Jirgensons A
    Bioorg Med Chem; 2018 May; 26(9):2488-2500. PubMed ID: 29636223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin D-mediated proteolysis of apolipoprotein E: possible role in Alzheimer's disease.
    Zhou W; Scott SA; Shelton SB; Crutcher KA
    Neuroscience; 2006 Dec; 143(3):689-701. PubMed ID: 16997486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin].
    Rumsh LD; Mikhaĭlova AG; Mikhura IV; Prudchenko IA; Chikin LD; Mikhaleva II; Kaliberda EN; Dergousova NI; Mel'nikov EE; Formanovskiĭ AA
    Bioorg Khim; 2008; 34(6):739-46. PubMed ID: 19088746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition.
    Rich DH; Bernatowicz MS; Agarwal NS; Kawai M; Salituro FG; Schmidt PG
    Biochemistry; 1985 Jun; 24(13):3165-73. PubMed ID: 3927973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calculating proton uptake/release and binding free energy taking into account ionization and conformation changes induced by protein-inhibitor association: application to plasmepsin, cathepsin D and endothiapepsin-pepstatin complexes.
    Alexov E
    Proteins; 2004 Aug; 56(3):572-84. PubMed ID: 15229889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of subsite binding specificity of human cathepsin D through kinetics and rule-based molecular modeling.
    Scarborough PE; Guruprasad K; Topham C; Richo GR; Conner GE; Blundell TL; Dunn BM
    Protein Sci; 1993 Feb; 2(2):264-76. PubMed ID: 8443603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dynamics and free energy analyses of cathepsin D-inhibitor interactions: insight into structure-based ligand design.
    Huo S; Wang J; Cieplak P; Kollman PA; Kuntz ID
    J Med Chem; 2002 Mar; 45(7):1412-9. PubMed ID: 11906282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.